Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1998 3
1999 1
2000 2
2001 3
2002 5
2003 1
2004 3
2007 4
2008 5
2009 5
2010 5
2011 4
2012 2
2013 5
2014 4
2015 5
2016 5
2017 4
2018 4
2019 2
2021 3
2022 6
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

71 results
Results by year
Filters applied: . Clear all
Page 1
Targeting PARP-1 with metronomic therapy modulates MDSC suppressive function and enhances anti-PD-1 immunotherapy in colon cancer.
Ghonim MA, Ibba SV, Tarhuni AF, Errami Y, Luu HH, Dean MJ, El-Bahrawy AH, Wyczechowska D, Benslimane IA, Del Valle L, Al-Khami AA, Ochoa AC, Boulares AH. Ghonim MA, et al. Among authors: boulares ah. J Immunother Cancer. 2021 Jan;9(1):e001643. doi: 10.1136/jitc-2020-001643. J Immunother Cancer. 2021. PMID: 33495297 Free PMC article.
PARP inhibition protects against alcoholic and non-alcoholic steatohepatitis.
Mukhopadhyay P, Horváth B, Rajesh M, Varga ZV, Gariani K, Ryu D, Cao Z, Holovac E, Park O, Zhou Z, Xu MJ, Wang W, Godlewski G, Paloczi J, Nemeth BT, Persidsky Y, Liaudet L, Haskó G, Bai P, Boulares AH, Auwerx J, Gao B, Pacher P. Mukhopadhyay P, et al. Among authors: boulares ah. J Hepatol. 2017 Mar;66(3):589-600. doi: 10.1016/j.jhep.2016.10.023. Epub 2016 Oct 29. J Hepatol. 2017. PMID: 27984176
Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases.
Berger NA, Besson VC, Boulares AH, Bürkle A, Chiarugi A, Clark RS, Curtin NJ, Cuzzocrea S, Dawson TM, Dawson VL, Haskó G, Liaudet L, Moroni F, Pacher P, Radermacher P, Salzman AL, Snyder SH, Soriano FG, Strosznajder RP, Sümegi B, Swanson RA, Szabo C. Berger NA, et al. Among authors: boulares ah. Br J Pharmacol. 2018 Jan;175(2):192-222. doi: 10.1111/bph.13748. Epub 2017 Mar 26. Br J Pharmacol. 2018. PMID: 28213892 Free PMC article. Review.
Targeting the Cbl-b-Notch1 axis as a novel immunotherapeutic strategy to boost CD8+ T-cell responses.
Monticone G, Huang Z, Csibi F, Leit S, Ciccone D, Champhekar AS, Austin JE, Ucar DA, Hossain F, Ibba SV, Boulares AH, Carpino N, Xu K, Majumder S, Osborne BA, Loh C, Miele L. Monticone G, et al. Among authors: boulares ah. Front Immunol. 2022 Aug 26;13:987298. doi: 10.3389/fimmu.2022.987298. eCollection 2022. Front Immunol. 2022. PMID: 36090975 Free PMC article.
Swimming and the human microbiome at the intersection of sports, clinical, and environmental sciences: A scoping review of the literature.
Puce L, Hampton-Marcell J, Trabelsi K, Ammar A, Chtourou H, Boulares A, Marinelli L, Mori L, Cotellessa F, Currà A, Trompetto C, Bragazzi NL. Puce L, et al. Among authors: boulares a. Front Microbiol. 2022 Aug 3;13:984867. doi: 10.3389/fmicb.2022.984867. eCollection 2022. Front Microbiol. 2022. PMID: 35992695 Free PMC article. Review.
71 results